AUSTIN, Texas / Feb 21, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information:
Event: | Natera’s Fourth Quarter and Year-End 2022 Financial Results | |
Date: | Tuesday, Feb. 28, 2023 | |
Time: | 1:30 p.m. PT (4:30 p.m. ET) | |
Live Dial-In: | 1 (888) 770-7321, Domestic | |
| 1 (929) 201-7107, International | |
Conference ID: | 7684785 | |
Webcast: |
A webcast replay will be available at investor.natera.com.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Last Trade: | US$141.17 |
Daily Change: | -6.91 -4.67 |
Daily Volume: | 414,236 |
Market Cap: | US$18.640B |
March 25, 2025 March 10, 2025 February 27, 2025 January 25, 2025 January 21, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load